CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors, have produced remarkably durable responses in advanced non-small-cell lung cancer (NSCLC) (Qu et al., 2021).